Deka Biosciences

Transforming Healthcare Through Precision & Innovation

Guided by our commitment to develop cures, we are revolutionizing cancer and inflammatory treatments.

Next-Generation Cytokine Therapy

The Diakine™ platform is a next-generation cytokine therapy created to treat cancer and inflammatory disease based on each patient’s individual immune response.

Our Oncology Platform

The different Diakines™  are composed of a disease-targeting scaffold that links together the combination of cytokines that safely stimulate the immune system to destroy cancer cells.
Cytokines are naturally occurring, small proteins that control the immune system. Using single cytokines to treat cancer can be effective, but is often toxic.
The Diakine™ platform combines the potent anti-cancer function of stimulatory cytokines like interleukin-2, with the inflammation-controlling function of a cytokine like interleukin-10, and targets these cytokines to the tumor, using a human single-chain variable antibody fragment.
By combining the natural functions of two different cytokines, the Diakine™ platform can increase anti-cancer immunostimulatory function while reducing risk of toxic side effects – maximizing the overall potential of the immune system to fight cancer.

Our Precision Medicine

People respond differently to various cytokine combinations. Drawing from years of research, we are now able to determine underlying cellular reactions that help us predict each patient’s immune response to different Diakines™. 
For cancer, we have reduced the complexities of anti-cancer immunity to an in-vitro assay that assesses the induced secretion of IFN-gamma by CD8+ T cells after exposure to each Diakine™.
This test permits the evaluation of each patient’s immune response to the different combinations of cytokines, which has the potential to predict treatment response.
When testing for inflammatory disease, we use a different in-vitro assay with Toll-like receptor agonists measuring stimulated monocytes secretion and response to IL-10 to determine who will potentially benefit the most from treatment with an anti-inflammatory Diakine™. 
Our mission is to continue to develop simple genetic tests to enable treating physicians to choose the most effective Diakine™ for each patient.

Designed for Your Journey

Our vision is that each patient’s DiakineTM will be an optimal combination of cytokines for their genetic signature.

Our Promise

We are developing treatments for inflammatory disease and cancer by combining precision patient selection with novel immunotherapies. We are steadfast in our mission to make these therapies effective, safe, and accessible, enabling self-administered treatment in the comfort of your home.
Deka’s first clinical trial: DEKA-1
Who is this trial designed for?
What is DK210 (EGFR)?
Mechanism of Action (MOA)
Source: https://www.dekabiosciences.com/